ERBB2 and gastric cancer: Here, we report the results of a single-arm, multi-institutional phase Ib/II trial evaluating a quadruplet regimen of pembrolizumab, trastuzumab, capecitabine, and cisplatin as a first-line therapy for HER2-positive advanced gastric cancer (AGC) with post hoc genomic studies (PANTHERA trial).